Matches in SemOpenAlex for { <https://semopenalex.org/work/W2732295890> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2732295890 abstract "Background: Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. We have previously reported that mediators of inflammation, such as COX-2, promote the growth of Triple-Negative receptor (TN) IBC xenografts; therefore, inflammation in TN-IBC has a unique opportunity as a therapeutic strategy. Eicosapentaenoic acid (EPA), a non-toxic omega-3 fatty acid with anti-inflammatory properties, has partially reduced tumor growth in pre-clinical models of TN-IBC. Therefore, our goal is to develop a novel non-toxic approach that enhances EPA efficacy against TN-IBC in combination with targeted therapy. Methods and Results: Using a high-throughput, siRNA screen (939 genes) in the TN-IBC cell line SUM149PT, we identified Ephrin type-A receptor 2 (EPHA2), an oncogenic cell-surface receptor tyrosine kinase, as a target that modulates the sensitivity of TN-IBC cells to EPA treatment. To determine the clinical relevance of EPHA2, we interrogated a meta-analysis of breast cancer mRNA expression data sets, and found that high EPHA2 tumor expression was significantly correlated with poor overall survival in TN-IBC patients, compared to low EPHA2 expressing tumors (P = 0.01). We observed no significant correlations to other breast cancer subtypes. Similar findings were observed in vitro were EPHA2 expression predominantly occurred in the TN-IBC subtypes (19 of 30) among 49 breast cancer cell lines. Gain/loss-of-expression studies were performed to functionally validate EPHA2 as a synergistic combinational target with EPA in two EPHA2-expressing TN-IBC models, SUM149PT and BCX010, using proliferation and apoptosis assays in vitro and established tumor xenografts in vivo. EPHA2 gene silencing significantly reduced cell growth and induced apoptosis in combination with EPA when compared with untreated control and monotherapy in vitro (P Conclusions: Our preclinical findings provide a rationale for the development of a phase 1 clinical trial investigating combination EPA and EPHA2-inhibitors in patients with EPHA2-positive TN-IBC. Citation Format: Angie M. Torres-Adorno, Heidi Vitrac, Yuan Qi, Yiwen Yang, Peiying Yang, Bedrich L. Eckhardt, Naoto T. Ueno. EPHA2-targeted therapy enhances the cytotoxicity of eicosapentaenoic acid against triple-negative inflammatory breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1235. doi:10.1158/1538-7445.AM2017-1235" @default.
- W2732295890 created "2017-07-14" @default.
- W2732295890 creator A5003693436 @default.
- W2732295890 creator A5037780494 @default.
- W2732295890 creator A5048206365 @default.
- W2732295890 creator A5063903344 @default.
- W2732295890 creator A5065117192 @default.
- W2732295890 creator A5069311994 @default.
- W2732295890 creator A5088814426 @default.
- W2732295890 date "2017-07-01" @default.
- W2732295890 modified "2023-09-24" @default.
- W2732295890 title "Abstract 1235: EPHA2-targeted therapy enhances the cytotoxicity of eicosapentaenoic acid against triple-negative inflammatory breast cancer" @default.
- W2732295890 doi "https://doi.org/10.1158/1538-7445.am2017-1235" @default.
- W2732295890 hasPublicationYear "2017" @default.
- W2732295890 type Work @default.
- W2732295890 sameAs 2732295890 @default.
- W2732295890 citedByCount "0" @default.
- W2732295890 crossrefType "proceedings-article" @default.
- W2732295890 hasAuthorship W2732295890A5003693436 @default.
- W2732295890 hasAuthorship W2732295890A5037780494 @default.
- W2732295890 hasAuthorship W2732295890A5048206365 @default.
- W2732295890 hasAuthorship W2732295890A5063903344 @default.
- W2732295890 hasAuthorship W2732295890A5065117192 @default.
- W2732295890 hasAuthorship W2732295890A5069311994 @default.
- W2732295890 hasAuthorship W2732295890A5088814426 @default.
- W2732295890 hasConcept C101544691 @default.
- W2732295890 hasConcept C121608353 @default.
- W2732295890 hasConcept C126322002 @default.
- W2732295890 hasConcept C143998085 @default.
- W2732295890 hasConcept C150582083 @default.
- W2732295890 hasConcept C170493617 @default.
- W2732295890 hasConcept C19038510 @default.
- W2732295890 hasConcept C2776091944 @default.
- W2732295890 hasConcept C2780110267 @default.
- W2732295890 hasConcept C2780839634 @default.
- W2732295890 hasConcept C502942594 @default.
- W2732295890 hasConcept C530470458 @default.
- W2732295890 hasConcept C543025807 @default.
- W2732295890 hasConcept C55493867 @default.
- W2732295890 hasConcept C71924100 @default.
- W2732295890 hasConcept C86803240 @default.
- W2732295890 hasConcept C98274493 @default.
- W2732295890 hasConceptScore W2732295890C101544691 @default.
- W2732295890 hasConceptScore W2732295890C121608353 @default.
- W2732295890 hasConceptScore W2732295890C126322002 @default.
- W2732295890 hasConceptScore W2732295890C143998085 @default.
- W2732295890 hasConceptScore W2732295890C150582083 @default.
- W2732295890 hasConceptScore W2732295890C170493617 @default.
- W2732295890 hasConceptScore W2732295890C19038510 @default.
- W2732295890 hasConceptScore W2732295890C2776091944 @default.
- W2732295890 hasConceptScore W2732295890C2780110267 @default.
- W2732295890 hasConceptScore W2732295890C2780839634 @default.
- W2732295890 hasConceptScore W2732295890C502942594 @default.
- W2732295890 hasConceptScore W2732295890C530470458 @default.
- W2732295890 hasConceptScore W2732295890C543025807 @default.
- W2732295890 hasConceptScore W2732295890C55493867 @default.
- W2732295890 hasConceptScore W2732295890C71924100 @default.
- W2732295890 hasConceptScore W2732295890C86803240 @default.
- W2732295890 hasConceptScore W2732295890C98274493 @default.
- W2732295890 hasLocation W27322958901 @default.
- W2732295890 hasOpenAccess W2732295890 @default.
- W2732295890 hasPrimaryLocation W27322958901 @default.
- W2732295890 hasRelatedWork W1596890137 @default.
- W2732295890 hasRelatedWork W1957979130 @default.
- W2732295890 hasRelatedWork W1995345390 @default.
- W2732295890 hasRelatedWork W2037535832 @default.
- W2732295890 hasRelatedWork W2064116844 @default.
- W2732295890 hasRelatedWork W2070164503 @default.
- W2732295890 hasRelatedWork W2094396107 @default.
- W2732295890 hasRelatedWork W2323292100 @default.
- W2732295890 hasRelatedWork W2329016057 @default.
- W2732295890 hasRelatedWork W2397108424 @default.
- W2732295890 hasRelatedWork W2404476139 @default.
- W2732295890 hasRelatedWork W2567622012 @default.
- W2732295890 hasRelatedWork W2741142739 @default.
- W2732295890 hasRelatedWork W2766167625 @default.
- W2732295890 hasRelatedWork W2887410406 @default.
- W2732295890 hasRelatedWork W2887509926 @default.
- W2732295890 hasRelatedWork W2887583339 @default.
- W2732295890 hasRelatedWork W2955178987 @default.
- W2732295890 hasRelatedWork W3013380505 @default.
- W2732295890 hasRelatedWork W2177303538 @default.
- W2732295890 isParatext "false" @default.
- W2732295890 isRetracted "false" @default.
- W2732295890 magId "2732295890" @default.
- W2732295890 workType "article" @default.